Teva VP Ika Abravanel resigns
The Intra Uterine Ball is based on shape memory alloy used widely for various medical devices.
Ocon Medical Ltd. has begun human clinical trials of its new contraceptive intrauterine device (IUD) - the IUB (Intra Uterine Ball), a technological breakthrough in the contraceptives market. It is based on a shape memory alloy used widely for various medical devices, such as coronary artery stents.
The IUB has been inserted in ten women in Europe to date and is due to be inserted in additional women. Interim results of the clinical trial are encouraging with the participating women reporting high satisfaction with the product.
The IUB is meant to reduce common side effects of IUDs, like menorrhagia and discomfort, as well as reducing the risks incurred during insertion. In contrast with current IUDs, the IUB is a three dimensional device that is formed to be fully compatible with the uterine cavity. its unique profile will enable it to serve other functions and indications in women's health beside contraception, such as a drug eluting platform.
Dr. Ilan Baram, a senior gynecologist, founded Ocon Medical in 2011, with the support of the Office of the Chief Scientist and Docor International Management Ltd. through Van Leer Ventures Jerusalem Ltd.
Ocon Medical CEO Ariel Weinstein said, “Answering an unmet need, the IUB is great news for any woman seeking a safe and comfortable contraceptive solution that does not involve highly deterring hormones, a combination that has not existed until now. We expect to gain substantial market share from copper and hormone eluting IUDs."
Ocon Medical says that IUD's have become the most common means of reversible contraception in the world, with more than 185 million users, an estimated market of over $1.6 billion a year and strong growth. A recent opinion published by the US Food and Drug Administration (FDA) includes a recommendation to use IUDs for contraception by nulliparous women, including teenagers, in addition to childbearing women. The company expects the IUB to draw renewed attention to IUDs by women and should contribute to expanding the IUD use. Several recent medical publications, including in the New England Journal of Medicine cite the superiority of IUDs in terms of effectiveness (20 times more effective in pregnancy prevention than contraceptive pills for young women), and lower cost compared with other reversible contraceptive methods such as the pill and condoms.
Published by Globes [online], Israel business news - www.globes-online.com - on July 31, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.